// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal ciprofloxacin in bronchiectasis: results from the ORBIT-3 and -4 studies

James D. Chalmers - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Liposomal ciprofloxacin

Performing follow up chest x-rays for patients with a recent pneumonia leads to a significant number of other malignant and non-malignant pathologies being diagnosed

Peter Dobson - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

What’s important for people with NTM? An EMBARC-ELF patient survey

Michal Shteinberg - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa

Michaela Donaghy - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Influenza point-of-care testing: what is the point?

Matthew Maycock - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Influenza

N/A

Dual RNASeq unveils NTHi-macrophage transcriptomic changes during intracellular persistence

Jodie Ackland - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Azurocidin-1: a marker of COPD severity and microbial dysbiosis

Jennifer Pollock - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Dysbiosis

azurocidin

Neutrophil elastase is correlated with disease severity in a cohort from Southern Europe

Andrea Gramegna - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Elaszym

Evaluating salivary IgA levels as a biomarker for susceptibility to upper respiratory tract infection in elite athletes

Scarlett Turner - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The adaptation of a point of care test for the quantitative determination of active neutrophil elastase in sputum

Darragh McCafferty - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Elaszym

Validation of an activity-based immunoassay for measurement of active cathepsin g in sputum

Darragh McCafferty - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Radiological features of NTM pulmonary disease in patients with bronchiectasis

James D. Chalmers - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Bronchiectasis in Italy: data from the national registry IRIDE

Stefano Aliberti - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

Launch of a novel intrapleural fibrinolytic service for empyema at a district general hospital in London

Ewan Mackay - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

Dornase alpha

Incidence of Cardiac Complications after Hospitalisation for Community Acquired Pneumonia: A Large Population-based Cohort Study

Vadsala Baskaran - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

N/A

Meta-analysis of Acute Coronary Syndrome in Patients with Community-Acquired Pneumonia

Vadsala Baskaran - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

N/A

Pulmonary sarcoid-like granulomatosis during tumour necrosis factor-alpha inhibition: a scoping review

Allison Michaud - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Sarcoidosis

N/A

Characterisation of patients with chronic hypersensitivity pneumonitis (CHP - a seven year single centre experience

Abhinav Tiwari - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Extrinsic allergic alveolitis

N/A

Cardiac symptoms are a survival predictor in sarcoidosis

Theresia Mikolasch - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiac sarcoidosis

N/A

The effect of CPAP on quality of life in patients with ‘very’ mild Obstructive Sleep Apnoea (OSA: Results from a subset of the MERGE Randomised Trial

Julia Kelly - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Sleep apnoea

N/A

Copyright © 2026. QuantiNova All rights reserved